Research Topics
| F EdererSummaryAffiliation: The EMMES Corporation Country: USA Publications
| Collaborators
|
Detail Information
Publications
Fecal occult blood screening in the Minnesota study: role of chance detection of lesionsF Ederer
Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, USA
J Natl Cancer Inst 89:1423-8. 1997..This study was conducted to determine how much of the reduction resulted from chance detection...
The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year resultsFred Ederer
The Advanced Glaucoma Intervention Study, AGIS Coordinating Center, 401 North Washington Street, Suite 700, Rockville, MD 20850, USA
Ophthalmology 111:651-64. 2004..To present for black and white patients with medically uncontrolled glaucoma 10-year results of treatment with 1 of 2 randomly assigned surgical intervention sequences...
Fecal occult blood screening in the Minnesota study: sensitivity of the screening testT R Church
Division of Environmental and Occupational Health, School of Public Health, University of Minesota, Minneapolis 55455, USA
J Natl Cancer Inst 89:1440-8. 1997..Given these contradictions, we examined screening sensitivity for colorectal cancer in the Minnesota study by several direct and indirect methods...
Colorectal cancer mortality: effectiveness of biennial screening for fecal occult bloodJ S Mandel
Division of Environmental and Occupational Health, School of Public Health, University of Minnesota, Minneapolis 55455, USA
J Natl Cancer Inst 91:434-7. 1999..Herein, we provide updated results-through 18 years of follow-up--from the Minnesota trial that address the apparent inconsistent findings among the trials regarding biennial screening...
The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuationsJonghyeon Kim
The EMMES Corporation, Rockville, Maryland, USA
Ophthalmology 111:2109-16. 2004..When the number of confirmatory tests is increased from 1 to 2, the percentage of eyes that show a persistent defect increases from 72% to 84%...
